LifeArc spends Keytruda cash on R&D ignored by pharma
Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Deal with MRCT will look for potential new drug targets and candidates.